Search

everythinglearnresearchcommunity

for

Search:↓

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Atopic dermatitis in kids with alopecia areata can predict poor response to topical immunotherapy.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

People with moderate hair loss from Alopecia Areata feel more impacted than those with no or almost complete hair loss, and are more likely to seek treatment.

Access to JAK inhibitor therapy for alopecia areata patients is difficult, especially for racial minorities.

Alopecia areata may lead to hearing loss.

A patient with a rare chromosome condition also had a rare type of hair loss.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Serum from alopecia patients does not stop hair growth in grafted skin on mice.

Illness perception affects mental health and quality of life in Chinese alopecia patients.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

People with alopecia areata may be more likely to have a certain type of hearing loss.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

Many patients with Alopecia Areata in Korea experience anxiety, depression, and reduced quality of life, which are often unrelated to the severity of hair loss.

Younger patients with severe alopecia areata often have nail problems.

Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.

Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.

The main goal for new Alopecia Areata treatments should be significant improvement in scalp hair growth.

A patient with leukemia/lymphoma also had multiple autoimmune diseases, suggesting a link between them.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Koilonychia in alopecia areata can improve with oral corticosteroids.

Adults with alopecia areata stick to their medication better than those with atopic dermatitis.

Systemic steroids temporarily improve severe alopecia areata in children but often lead to relapse.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.